Cancer
The Monash Partners Comprehensive Cancer Consortium (MPCCC) brings together health services, research institutes and universities to improve outcomes for people affected by cancer. As the Cancer and Blood Diseases Theme of Monash Partners, MPCCC fosters collaboration across research, clinical care and health services to drive innovation in cancer prevention, early detection, treatment and survivorship.
By connecting expertise in translational, clinical, population health and health services research with the experience of clinical partners, MPCCC works to improve patient outcomes and experiences across the cancer care continuum.
Guided by the needs of consumers and communities, the consortium supports a coordinated approach to advancing cancer research, strengthening data-driven improvements in care, building capacity for innovation and fostering strategic partnerships that deliver lasting impact.
Learn more about the Monash Partners Comprehensive Cancer Consortium (MPCCC)
Leadership
Professor Mark Shackleton
Monash Partners Comprehensive Cancer Consortium Co-DirectorProfessor Melissa Southey
Monash Partners Comprehensive Cancer Consortium Co-DirectorDr Edmond Kwan
Early and Mid-Year Career Researcher Co-LeadCurrent Projects
Meeting optimal care pathways through real-time data-driven lung cancer care
This project will develop a live dashboard to monitor Optimal Care Pathway (OCP) timeframes, helping healthcare teams identify and address delays in lung cancer care more quickly.
Read More
Plasma immunopeptidomics for actionable target discovery in Acute Myeloid Leukaemia
This project aims to identify new cancer-specific immune markers that can be detected in a simple blood sample, making disease monitoring less invasive and potentially allowing relapse to be detected earlier.
Read More
Service capacity and equity in later-line lung cancer care
This project will compare access to second- and third-line lung cancer treatments in regional and metropolitan hospitals across Victoria. It will also examine differences in staffing, infrastructure, specialist services and the experiences of regional patients. The findings will help identify practical ways to improve cancer services and support more equitable lung cancer care for people living in regional communities.
Read More
Leveraging investigator-initiated clinical trials and novel therapeutic strategies to improve outcomes of older adults with acute myeloid leukaemia
This project aims to support analysis of trial results and the development of new treatment approaches, with the ultimate goal of extending survival and providing more personalised care for people with AML.
Read More
Resistance-guided sequencing of CAR T-Cell and bispecific antibody therapies in high-risk B-cell lymphomas: A translational immunogenomic approach
This project will investigate why some patients respond better to newer immunotherapy treatments than others by combining clinical information with advanced genetic research. In the longer term, the findings could help clinicians make more informed treatment decisions and support more personalised lymphoma care across the regional and rural catchment.
Read More
Dual PI3K/BET inhibition as a therapeutic strategy in T cell lymphoma
This project aims to determine whether 18DS, a new experimental drug designed to block two pathways cancer cells use to grow and survive, could be effective against T-cell lymphomas, and to better understand how the drug works, to help guide the development of future treatments.
Read More
Discovering novel epigenetic targets for future combinational immunotherapy trials in brain cancer
This project will establish a new brain tumour biobank for primary and metastatic brain cancer samples and undertake detailed immunology research on these tumours. By systematically collecting and analysing human brain tissue samples, the biobank will support research into the genetic and immune factors that influence brain cancer development and progression, with the aim of identifying new insights to inform future treatment strategies.
Read More
Redefining genotyping in metastatic prostate cancer: a liquid biopsy strategy for equitable access
This project will investigate whether circulating tumour DNA (ctDNA)—small fragments of cancer DNA detected through a specialised blood test—can accurately identify key genetic changes in people with newly diagnosed advanced prostate cancer, potentially reducing the need for invasive tissue biopsies. The study will also examine how these genetic features evolve over time in response to treatment.
Read More
Exploring feasibility of low intensity induction followed by allogeneic stem cell transplantation for Acute Myeloid Leukaemia
This project will develop a clinical trial to examine whether newer combination drug therapies for achieving remission in acute myeloid leukaemia (AML) are suitable for a broader group of patients undergoing planned bone marrow transplantation.
Read More
Monash Partners Support
Ms Lingzhi Ruan
Program Manager
